Eli Lilly & CO

Eli Lilly and Company has successfully completed a significant debt offering, raising approximately $8.94 billion to fund its operations and strategic initiatives.

Eli Lilly and Company held its 2026 Annual Meeting of Shareholders on May 4, 2026, where key director elections, executive compensation, auditor ratification, and several governance proposals were put to a vote.

Eli Lilly reported a 56% revenue increase in Q1 2026, driven by strong volume growth, and raised its full-year financial guidance.

Eli Lilly reports robust fourth-quarter 2025 financial results with 43% revenue growth and strong 2026 guidance, driven by key obesity and diabetes medicines.

Eli Lilly and Company announced the election of Dr. Carolyn R. Bertozzi, a distinguished Stanford professor and Nobel laureate, to its Board of Directors, effective December 8, 2025.

Eli Lilly and Company reported a robust 54% increase in third-quarter 2025 revenue to $17.60 billion, driven by strong demand for Mounjaro and Zepbound, and raised its full-year financial guidance.

Eli Lilly reports a significant 56% revenue increase in Q1 2026, driven by strong performance of Mounjaro and Zepbound, alongside substantial net income growth.

Eli Lilly reports exceptional Q3 and YTD 2025 financial results, driven by surging demand for Mounjaro and Zepbound, alongside significant pipeline advancements.

Eli Lilly reports exceptional Q2 and H1 2025 financial results, driven by surging demand for Mounjaro and Zepbound, alongside significant pipeline advancements.

Eli Lilly's Q1 2025 revenue surged by 45% year-over-year, fueled by strong sales of Mounjaro and Zepbound.

Eli Lilly's Q3 2024 results show significant revenue growth driven by Mounjaro and Zepbound, though increased R&D and marketing expenses impacted net income.

Eli Lilly's Q2 2024 earnings surged, fueled by robust sales of Mounjaro and Zepbound, alongside growth in other key products.

Eli Lilly reported exceptional financial growth in 2025, driven by strong demand for its cardiometabolic health products, while navigating a complex regulatory and competitive landscape.

Eli Lilly's 2024 annual report highlights significant revenue growth driven by key products like Mounjaro and Zepbound, alongside strategic investments in research and development and manufacturing capacity.

Eli Lilly's 10-K filing outlines the structure of its common stock, dividend rights, liquidation rights, voting rights, and various anti-takeover provisions.

Melissa Seymour, EVP, Global Quality of ELI LILLY & Co, reported multiple transactions in common stock on August 1, 2026.

Gabrielle Sulzberger, a Director of ELI LILLY & Co, received 4 shares of common stock on July 20, 2026.

Juan R Luciano, a Director of ELI LILLY & Co, received 14 shares of common stock on July 20, 2026.

J Erik Fyrwald, a Director of ELI LILLY & Co, received 9 shares of common stock on July 20, 2026.

Ralph Alvarez, a Director of ELI LILLY & Co, received 11 shares of common stock on July 20, 2026.

Eli Lilly Director Gabrielle Sulzberger acquired stock units valued at $1,129.35 as part of her compensation.

Eli Lilly reports exceptional 2025 financial and pipeline performance, alongside proposals to enhance corporate governance for shareholder approval.

Eli Lilly has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Eli Lilly seeks shareholder approval to eliminate its classified board structure and supermajority voting provisions, enhancing corporate governance.

Eli Lilly and Company has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Eli Lilly's proxy statement details a push to eliminate its classified board and supermajority voting requirements, alongside a review of its strong 2023 financial and operational performance.

Eli Lilly and Company has reported a beneficial ownership of 7.3% in Scribe Therapeutics, Inc. following its IPO, acquiring shares through a convertible note conversion and direct purchase.

Eli Lilly and Company has reported a significant 11.9% beneficial ownership in Aktis Oncology, Inc. following its initial public offering.

Eli Lilly and Company has reported a significant beneficial ownership stake of 15.6% in ProQR Therapeutics N.V., holding 21,995,880 ordinary shares.

Eli Lilly and Company has reported beneficial ownership of 7.9% of Ionetix Corp's common stock as of April 9, 2026.

Lilly Endowment, Inc. has disclosed a beneficial ownership of 90,376,978 shares of Eli Lilly and Company common stock, representing 9.6% of the outstanding shares as of June 30, 2026.

Lilly Endowment, Inc. has disclosed a beneficial ownership of 91,896,978 shares, representing 9.7% of Eli Lilly and Company's common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G for Eli Lilly & Co, reporting 0% beneficial ownership following an internal corporate realignment.

Lilly Endowment, Inc. filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.8% of Eli Lilly and Company's common stock as of December 31, 2025.